Publications

A novel antigen biomarker for detection of high-level of Loa loa microfilaremia
Greene SE, Huang Y, Fischer K, Rosa BA, Martin J, Mitreva M, Yates D, Wanji S, Kamgno J, Budge P, Weil GJ, Fischer PU. PLoS Negl Trop Dis.2024 Sept 3;18(9):e0012461

The long and winding road towards new treatments against lymphatic filariasis and onchocerciasis
Risch F, Kazakov A, Specht S, Pfarr K, Fischer PU, Hoerauf A, Hübner MP. Trends Parasitol. 2024 Sep;40(9):829-845. doi: 10.1016/j.pt.2024.07.005. Epub 2024 Aug 8. PMID: 39122645

Distinguishing recrudescence from reinfection in lymphatic filariasis
Choi YJ, Fischer K, Méité A, Koudou BG, Fischer PU, Mitreva M. EBioMedicine. 2024 Jul;105:105188. doi: 10.1016/j.ebiom.2024.105188. Epub 2024 Jun 7. PMID: 38848649

Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia
Supali T, Djuardi Y; Santoso; Sianipar LR, Suryaningtyas NH, Alfian R, Destani Y, Iskandar E, Astuty H, Sugianto N, Fischer PU. Am J Trop Med Hyg. 2023 Nov 27;110(1):111-116. doi: 10.4269/ajtmh.23-0255. Print 2024 Jan 3. PMID: 38011734

Implementation and Outcomes of a Pilot Collaborative Surgical Hydrocele Training in Côte d’Ivoire
Montes K, Angoa G, Bjerum CM, Guira A, Kouadio OK, Ouattara AF, Weil GJ, Fischer PU, Meite A, Koudou BG, Budge PJ Am J Trop Med Hyg. 2023 Nov 13;110(1):194-198. doi: 10.4269/ajtmh.23-0554. Print 2024 Jan 3. PMID: 37956446

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria
Eneanya OA, Reimer LJ, Fischer PU, Weil GJ. Int Health. 2023 Sep 1;15(5):566-572. doi: 10.1093/inthealth/ihad029. PMID: 37096453

Safety and tolerability of moxidectin and ivermectin combination treatments of lymphatic filariasis in Cote d’Ivoire: A randomized controlled superiority study
Bjerum CM, Koudou BG, Ouattara AF, Lew D, Goss CW, Gabo PT, King CL, Fischer PU, Weil GJ, Budge PJ. PLoS Negl Trop Dis. 2023 Sep;17(9):e0011633

Pharmacokinetics of moxidectin combined with albendazole or albendazole plus diethylcarbamazine for bancroftian filariasis
Chhonker YS, Bjerum C, Bala V, Ouattara AF, Koudou BG, Gabo TP, Alsheri A, Meite A, Fischer PU, Weil GJ, King CL, Budge PJ, Murry DL. PLoS Negl Trop Dis. 2023 Aug;17(8):e0011567

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis
Greene SE, Huang Y, Curtis KC, King CL, Fischer PU, Weil GJ. PLoS Negl Trop Dis. 2023 Jun 7;17(6):e0011364. doi: 10.1371/journal.pntd.0011364. eCollection 2023 Jun. PMID: 37285374

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one does of ivermectin plus albendazole (IA) for treatment of onchocerciasis
Opoku, NO, Doe F, Dubben B, Fetcho N, Fischer K, Fischer PU, Gordor S, Goss CW, Gyasi ME, Hoerauf A, Hong AR, Kanza E, King CL, Weil GW. PLoS Negl Trop Dis. 2023 May;17(5):e0011365

Histopathological evaluation of Onchocerca volvulus nodules by microscopy and by digital image analysis for the study of macrofilaricidal drug efficacy
Fischer K, Dubben B, Debrah LB, Kuehlwein JM, Ricchiuto A, Debrah AY, Hoerauf A, Weil GJ, Fischer PU, Klarmann-Schulz U. Front Med. 2023 Feb 2;10

Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa
Stolk WA, Coffeng LE, Bolay FK, Eneanya OA, Fischer PU, Hollingsworth TD, Koudou BG, Méité A, Michael E, Prada JM, Caja Rivera RM, Sharma S, Touloupou P, Weil GJ, de Vlas SJ
PLoS Negl Trop Dis. 2022 Dec 12;16(12):e0010953. doi: 10.1371/journal.pntd.0010953. eCollection 2022 Dec. PMID: 36508458

Direct proteomic detection and prioritization of 19 onchocerciasis biomarker candidates in humans
Rosa BA, Curtis K, Erdmann Gilmore P, Martin J, Zhang Q, Sprung R, Weil GJ, Townsend RR, Fischer PU, Mitreva M
Mol Cell Proteomics. 2022 Nov 23;22(1)100454.

Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin
Ekpo UF, Eneanya OA, Nwankwo EN, Soneye IY, Weil GJ, Fischer PU, Nwaorgu OC
BMC Infect Dis. 2022 Nov 10;22(1):832.

Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections
Greene SE, Fischer K, Choi YJ, Curtis KC, Budge PJ, Mitreva M, King CL, Fischer PU, Weil G
PLoS Negl Trop Dis. 2022;16:e0010407

New Research Aims to Optimize Therapy Against Onchocerciasis
Hong AR, Opoku NO, Weil GJ, Kanza EM, Gyasi ME
Mo Med. 2022 Jan-Feb;119(1):55-59.

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial
Laman, M, Tavul, L, Karl, S, Kotty, B, Kerry, Z, Kumai, S, Samuel, A, Lorry, L, Timinao, L, Howard, SC, Makita, L, John, L, Bieb, S, Wangi, J, Albert, JM, Payne, M, Weil, GJ, Tisch, DJ, Bjerum, CM, Robinson, LJ, King, CL
Lancet Infect Dis. 2022;22:1200-09.

Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia
Eneanya, OA, Gankpala, L, Goss, CW, Momolu, AT, Nyan, ES, Gray, EB, Fischer, K, Curtis, K, Bolay, FK, Weil, GJ, Fischer, PU
Acta Tropica. 2022;231:106437.

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
Tavul, L, Laman, M, Howard, C, Kotty, B, Samuel, A, Bjerum, C, O’Brian, K, Kumai, S, Amuga, M, Lorry, L, Kerry, Z, Kualawi, M, Karl, S, Makita, L, John, LN, Bieb, S., Wangi, J, Weil, GJ, Goss, CW, Tisch, DJ, Pomat W, King C, Robinson, LJ
PLoS Negl Trop Dis. 2022;16(2):

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis
Weil, GJ, Fischer, PU, Krentel, A
Am J Trop Med Hyg. 2022;106(5 Suppl):13-17.

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis
Pantelias, A, King, JD, Lammie, P, Weil, GJ
Am J Trop Med Hyg. 2022;106(5 Suppl):56-60.

Semiannual treatment of Albendazole alone is efficacious for treatment of lymphatic filariasis: A randomized open-label trial in Cote d’Ivoire
Ouattara AF, Bjerum CM, Aboulaye M, Kouadio O, Marius VK, Andersen B, Lew D, Goss CW, Weil GJ, Koudou BG, King CL
Clin Infect Dis. 2022;74(12):2200-8.

Country reports for practical aspects of conducting large-scale community studies of the tolerability of mass drug administration with Ivermectin/Diethylcarbamazine/Albendazole for lymphatic filariasis
Jambulingam P, Subramanian S, Krishnamoorthy K, Supali T, Fischer P, Dubray C, Fayette C, Lemoine JF, Laman M, King C, Samuela J, Hardy M, Weil GJ
Am J Trop Med Hyg. 2022;106(5 Suppl):18-25.

A Reevaluation of the Tolerability and Effects of Single-Dose Ivermectin Treatment on Onchocerca volvulus Microfilariae in the Skin and Eyes in Eastern Ghana
Opoku, NO, Gyasi, ME, Doe, F, Lew, D, Hong, AR, Chithenga, S, Fischer, PU, King, CL, Weil, GJ
Am J Trop Med Hyg. 2022;106(2):740-745.

Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence
Campillo, JT, Awaca-Uvon, NP, Missamou, F, Tambwe, JP, Kuyangisa-Simuna, G, Weil, GJ, Louya, F, Boussinesq, M, Pion, S, & Chesnais, CB
Clin Infect Dis. 2021;73(1):e176-e183.

Diagnostics to support elimination of lymphatic filariasis-Development of two target product profiles
Won KY, Gass K, Biamonte M, Dagne, DA, Ducker C, Hanna C, Hoerauf A, Lammie PJ, Njenga SM, Noordin R, Ramaiah KD, Ramzy R, Scholte R, Solomon AW, Souza AA, Tappero J, Toubali E, Weil GJ, Williams SA, King JD
PLoS Negl Trop Dis. 2021;15(11):e0009968.

Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia
Eneanya, OA, Gankpala, L, Goss, CW, Bolay, FK, Weil, GJ, Fischer, PU
Am J Trop Med Hyg. 2021;106(2):700-709.

Impact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment
Pion, S, Chesnais, CB, Weil, GJ, Louya, F, Boussinesq, M, Missamou, F
Am J Trop Med Hyg. 2021;106(2):729-731.

Community control strategies for scabies: A cluster randomised noninferiority trial
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Schuster T, Grobler AC, Engelman D, Robinson LJ, Kaldor JM, Steer AC
PLoS Med. 2021;18(11):1-14.

Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence
Campillo JT, Awaca-Uvon NP, Missamou F, Tambwe JP, Kuyangisa-Simuna G, Weil GJ, Louya F, Boussinesq M, Pion SDS, Chesnais CB
Clin Infect Dis. 2021;73:e176-e183.

Individual efficacy and community impact of ivermectin, diethylcarbamazine and albendazole mass drug administration for lymphatic filariasis control in Fiji: a cluster randomised trial
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Grobler AC, Robinson LJ, Kaldor JM, Steer AC
Clinical Infectious Diseases. 2021;Mar 17:ciab202

A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
Krentel A, Basker N, Beau de Rochars M, Bogus J, Dilliott D, Direny AB, Dubray C, Fischer PU, Lomi Ga A, Goss CW, Hardy M, Howard C, Jambulingam P, King CL, Laman M, Lemoine JF, Mallya S, Robinson LJ, Samuela J, Schechtman KB, Steer AC, Supali T, Tavul L, Weil GJ
PLoS Negl Trop Dis. 2021;15(3):1-27.

An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
Supali T, Djuardi Y, Christian M, Iskandar E, Alfian R, Maylasari R, Destani Y, Lomiga A, Minggu D, Lew D, Bogus J, Weil GJ, Fischer PU
PLoS Negl Trop Dis. 2021;15(3):e0009294.

An open label, block randomized, community study of the safety and efficacy of co-administered ivermecting, diethylcarbamizine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ
PLoS Negl Trop Dis. 2021;15(2):1-26.

Progress towards onchocerciasis elimination in Cote d’Ivoire: A geospatial modelling study
Eneanya OA, Koudou BG, Meite A, Aba Ange E, Souleymane Y, Kouakou MM, Weil GJ, Fischer PU
PLoS Negl Trop Dis. 2021;15(2):1-19.

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
Weil GJ, Jacobson JA, King JD
Int Health. 2020;13(Suppl 1):S60-S64.

Motile Onchocerca volvulus Microfilariae in the Anterior Chamber of the Eye
Gyasi ME, Hong AR, Weil GJ
Am J Trop Med Hyg. 2020;102(5):921.

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Cote d’Ivoire
Loukouri A, Meite A, Koudou BG, Goss CW, Lew D, Weil GJ, N’Goran EK, Fischer PU
PLoS Negl Trop Dis. 2020;14(9):1-15.

Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: A randomized, open-label, clinical trial
Batsa Debrah L, Klarmann-Schultz U, Osei-Mensa J, Dubben B, Fischer K, Mubarik Y, Ayisi-Boateng MK, Ricchiuto A, Fimmers R, Kanadu P, Nadal J, Gruetzmacher B, Weil G,  Kazura JW, King CL, Debrah AY, Hoerauf A
Clin Infect Dis. 2020;71(4):933-943.

Single-Dose Triple-Drug Therapy for Wuchereria bancrofti — 5-Year Follow-up
King C , Weil GJ, Kazura JW
N Engl J Med. 2020;382(20):1956-1957.

The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo
Pion SDS, Chesnais CB, Awaca-Uvon NP, Vlaminck J, Abdou A, Kunyu-Shako B, Kuyangisa Simuna G, Tambwe JP, Weil GJ, Boussinesq M
PLoS Negl Trop Dis. 2020 14(6):1-12.

Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Cote d’Ivoire: an open-label, randomized, controlled trial
Bjerum CM, Ouattara AF, Meite A, Kouadio O, Marius VK, Andersen B, Weil GJ, Koudou BG, King CL
Clin Infect Dis. 2020;71(7):e68–e75.

The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Grobler AC, Robinson LJ, Kaldor JM, Steer AC
PLoS Negl Trop Dis. 2020;14(3):1-17.

Frequency and clinical significance of localized adverse events following mass drug administration for lymphatic filariasis in an endemic area in South India
Kuttiatt VS, Somani RK, Swaminathan S, Krishnamoorthy K, Weil GJ, Purushothaman J
Am J Trop Med Hyg. 2019;102(1):96-99.

Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
Andersen BJ, Rosa BA, Kupritz J, Meite A, Serge T, Hertz MI, Curtis K, King CL, Mitreva M, Fischer PU, Weil GJ
PLoS Negl Trop Dis. 2019;13(9):e0007697.

Dosing pole recommendations for lymphatic filariasis elimination: a height-weight quantile regression modeling approach
Goss CW, O’Brian K, Dubray C, Fischer PU, Hardy M, Jambulingam P, King CL, Laman M, Lemoine JF, Robinson L, Sameula J, Swaminathan S, Supali T, Weil GJ, Schechtman KB
PLoS Negl Trop Dis. 2019;13(7):e0007541.

The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y , Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS,  Krishnamoorthy K, Laman M, Lemoine, JF, OBrian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, The DOLF IDA Safety Study Group
PLoS Negl Trop Dis. 2019;16(6):e1002839.

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
Edi C, Bjerum CM, Koudou BG, Chhonker YS, Penali LK, Meite S, Ouattara AF, Weil GJ, King CL, Murry DJ
PLoS Negl Trop Dis. 2019;13(5):e0007325.

Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana KC, Puhchihewa MW, Ranasinghe USB, Weil GJ
PLoS Negl Trop Dis. 2019;13(4):e0007365.

Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo
Chenais CB, Awaca-Uvon NP, Vlaminck J, Tambwe JP, Weil GJ, Pion SD, Boussinesq M
Parasit Vectors. 2019;12:162.

Comparison of the impact of annual and semiannual mass drug administration on lymphatic filariasis prevalence in Flores Island, Indonesia
Supali T, Djuardi Y, Lomiga A,  Linda SN, Iskander E, Goss CW, Miller JP, Weil GJ, Fischer PU
Am J Trop Med Hyg. 2019;100(2):336-343.

A trial of a triple-drug treatment for lymphatic filariasis
King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, Goss CW, Robinson LJ, Siba PM, Weil GJ, Kazura JW
N Engl J Med. 2018;379(19):1801-1810.

 Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
Budge PJ, Herbert C, Andersen BJ, Weil GJ
PLoS Negl Trop Dis. 2018;12(5):e0006454.

Capillaria ova and Diagnosis of trichuris trichiura Infection in humans by kato-katz smear, Liberia
Fischer K, Gankpala A, Gankpala L, Bolay FK, Curtis KC, Weil GJ, Fischer PU
Emerg Infect Dis. 2018;24(8):1551-1554.

Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis
Hertz MI, Nana-Djeunga H, Kamgno J, Jelil Njouendou A, Chawa Chunda V, Wanji S, Budge PJ
PLoS Negl Trop Dis. 2018;12(11):e0006963.

Update on the current status of onchocerciasis in Cote d’Ivoire following 40 years of intervention: Progress and challenges
Koudou BG, Kouakou MM, Ouattara AF, Yeo S, Brika P, Meite A, Fischer PU
PLoS Negl Trop Dis. 2018;12(10):e0006897.

Comprehensive assessment of a hotspot with persistent bancroftian filariasis in coastal Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana KC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ
Am J Trop Med Hyg. 2018;99(3):735-742.

Changes in cytokine, filarial antigen, and DNA levels associated with adverse events following treatment of lymphatic filariasis
Andersen BJ, Kumar J, Curtis K, Sanuku N, Satafan S, King CL, Fischer PU, Weil GJ
J Infec Dis. 2018;217(2): 280- 287.

Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia
Rosa BA, Supali T, Gankpala L, Djuardi Y, Sartono E, Zhou Y, Fischer K, Martin J, Tyagi R, Bolay FK, Fischer PU, Yazdanbakhsh M, Mitreva M
Microbiome. 2018;6:33.

Reassessment of areas with persistent lymphatic filariasis nine years after cessation of mass drug administration in Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana DC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ
PLoS Negl Trop Dis. 2017;11(10):e0006066.

A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa
Chesnais CB, Awaca-Uvon NP, Bolay FK, Boussinesq M, Fischer PU, Gankpala L, Meite A, Missamou F, Pion SD, Weil GJ
PLoS Negl Trop Dis. 2017; 11(9):e0005703.

Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo
Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M
Lancet Infect Dis. 2017;17(7):763-769.

Potential value of triple Drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa
Fischer PU, King CL, Jacobson JA, Weil GJ
PLoS Negl Trop Dis. 2017;11(1):e0005163.

Use of a novel portable 3D scanner to measure limb volume and circumference in patients with filarial lymphedema
Yahathugoda C, Weiler M, Rao R, De Silva L, Dixon J, Weerasooriya M, Weil GJ, Budge P
Am J Trop Med Hyg. 2017;97(6):1836-1842.

Effectiveness of a triple-drug Regimen for global elimination of lymphatic filariasis: A modelling study
Irvine MA, Stolk WA , Smith ME, Subramanian S, Singh BK, Weil GJ, Michael E, Hollingsworth TD
Lancet Infect Dis. 2016;17(4):451-458.

Measurement of circulating filarial antigen levels in human blood with a point-of-care test strip and a portable spectrodensitometer
Chesnais CB , Vlaminck J , Kunyu-Shako B, Pion SD, Awaca-Uvon NP, Weil GJ, Mumba D, Boussinesq M 
Am J Trop Med Hyg. 2016;94(6):1324-1329.

Familial aggregation and heritability of Wuchereria bancrofti infection
Chesnais CB , Sabbagh A , Pion SD,  Missamou F, Garcia A, Boussinesq MJ 
J Infect Dis. 2016;214:587-594.

Programmatic use of molecular xenomonitoring at the level of evaluation units to assess persistence of lymphatic filariasis in Sri Lanka
Rao RU, Samarasekera SD , Nagadavithana KC , Punchilewa MW , Dassanayaka TDM , Gamini PKD, Ford E, Udaya S, Ranassinghe B, Henderson RH, Weil GJ 
PLoS Neglected Trop Dis. 2016;10(5):e0004722.

Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis
Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, Schmidt MS,  Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL
Clin Infect Dis. 2016;62(3):334-41.

Community attitudes toward mass drug administration for control and elimination of neglected tropical diseases after the 2014 outbreak of ebola virus disease in Lofa County, Liberia
Bogus J, Gankpala L, Fischer K, Krentel A, Weil GJ, Fischer PU, Kollie K, Bolay FK
Am J Trop Med Hyg. 2016;94(3):497-503.

A Comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration
TC Yahathugoda, T Supali, RU Rao, Y Djuardi, D Stefani, F Pical, PU Fischer, MM Lloyd, PH Premaratne, MV Weerasooriya, GJ Weil
Parasit Vectors. 2015;8:369.

The impact of two semi-annual treatments with Albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Republic of Congo
Pion SDS , Chesnais CB , Bopda J, Louya F, Fischer PU, Majewski AC, Weil GJ, Boussinesq M, Missamou F
Am J Trop Med Hyg. 2015;92(5):959-966.

Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes
Lloyd MM, Gilbert R, Taha NT, Weil GJ, Meite A, Kouakou IMM, Fischer PU
Acta Trop. 2015;146:114-118.

Diagnostic tools for onchocerciasis elimination programs
Vlaminck J, Fischer PU, Weil GJ
Trends Parasitol. 2015;31(11):571-82.

Filarial antigenemia and Loa loa night blood microfilaremia in an area without bancroftian filariasis in the Democratic Republic of Congo
Bakajika DK, Nigo MM , Lotsima JP , Masikini GA , Fischer K , Lloyd MM , Weil GJ, Fischer PU
Am J Trop Med Hyg. 2014;91(6):1142-1148.

A case study of risk factors for lymphatic filariasis in the Republic of Congo
Chesnais CB , Missamou F, Pion SD, Bopda J, Louya F, Majewski AC , Fischer PU, Weil GJ, Boussinesq M
Parasit Vectors. 2014;7:300.

A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration
Rao RU , Nagodavithana KC , Samarasekera SD , Wijegunawardana AD , Premakumara WDY , Perera SN , Settinayake S , Miller JP , Weil GJ
PLoS NTD. 2014;8(11):e3281.

Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies
Schmidt MS, King CL, Thomsen EK, Siba PM, Sanuku N, Fleckenstein L
J Pharm Biomed Anal. 2014;98:307-10.

Exploring the potential of flubendazole in filariasis control: Evaluation of the systemic exposure for different pharmaceutical preparations
Ceballos L, Mackenzie C, Geary T,  Alvarez L, Lanusse C
PLoS Negl Trop. 2014;8(5):e2838.

Integrated school-based surveillance for soil-transmitted helminth infections and lymphatic filariasis in Gampaha District, Sri Lanka
Gunawardena S, Gunawardena NK, Kahathuduwa G, Karunaweera ND, de Silva NR, Ranasinghe UB, Samarrasekara SD, Nagodavithana KC, Rao RU, Rebollo MP, Weil GJ
Am J Trop Med Hyg. 2014;90(4):661-666.

Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen
Chesnais CB, Missamou F, Pion SDS , BopdaJ , F Louya, Majewski AC, Weil GJ, Boussinesq M
Am J Trop Med Hyg. 2013;89(5):916-918.

A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis
Krentel A, Fischer PU, Weil GJ
PLoS Negl Trop. 2013;7(11):e2447.

Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood
Weil GJ, Curtis KC, Fakoli L, Fischer K, Gankpala L, Lammie PJ,  Majewski AC, Pelletreau S, Won KY, Bolay FK, Fischer PU
Am J Trop Med Hyg. 2013;89(1):11-15.

Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis
Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS
PLoS Negl Trop. 2013;7(1):e1984.

A review of flubendazole and its potential as a macrofilariacide
Mackenzie C
A report submitted to Dr. Gary Weil (PI DOLF) – a study supported by the Bill & Melinda Gates Foundation.

Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs
Mackenzie CD,  Geary TG
Expert Rev Anti Infect Ther. 2011;9(5):497-501.